The “2024 Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report” has been added to ResearchAndMarkets.com’s offering.
The landscape of biopharmaceutical clinical development is in a constant state of flux and progression. While major global Contract Research Organizations (CROs) cater to a significant portion of the clinical development needs within the biopharma industry, Clinical Site Networks are assuming an increasingly pivotal role in facilitating the achievement of clinical trial objectives for both biopharma sponsors and CROs.
This comprehensive report, derived from insights gathered from 63 professionals within the biopharma industry across North America and Europe, delves into the current dynamics of interactions between biopharma sponsors and clinical site networks. Moreover, it offers a glimpse into the anticipated trends and expectations in this domain over the coming 1-2 years. Additionally, the report examines the allocation of biopharma sponsors’ outsourcing expenditures among various external partners, including CROs, Site Networks, and Academic institutions. Furthermore, it underscores the advantages of biopharma sponsors forging direct partnerships with Clinical Site Networks as opposed to accessing them through intermediary CROs.
The analysts behind this report provide valuable commentary and analysis, drawing upon over three decades of experience consulting with leading global biopharmaceutical companies, clinical development CROs, and industry analysts specializing in CROs.
Noteworthy companies covered in the report include:
- IQVIA
- ICON
- Parexel
- Fortrea (formerly Labcorp)
- PPD/Thermo Fisher
- Syneos Health
